TPE Methods Explained: Centrifugal vs Membrane

What this means

Therapeutic plasma exchange (TPE) can separate plasma from blood cells in two engineering ways. Centrifugal TPE (cTPE) spins whole blood so layers form by density; plasma is skimmed off and cells return with replacement fluid. Membrane TPE (mTPE) pushes blood along a filter that lets plasma through pores while cells stay in the circuit. ASFA defines both as TPE. In journals, plasmapheresis often means the same clinical procedure regardless of hardware.

Patients hear brand names and assume one method is “true plasma exchange” and the other is dialysis theater. That is not how indications work. The clinical act is removing a prescribed plasma volume and replacing it with albumin or donor plasma. Hardware changes efficiency, blood-flow needs, access, and sometimes citrate load. It does not by itself treat aging.

This distinction matters because longevity marketing may boast a hospital-grade centrifuge or a “medical filter.” TPE remains a specialty procedure for specific diseases. Longevity TPE is speculative, costly, and not a proven aging treatment. Infection, clotting, hypocalcemia, and access complications occur with both circuits.

What the evidence shows

A randomized crossover study in PMC compared membrane and centrifuge TPE using albumin replacement. Centrifugal TPE showed higher plasma-removal efficiency (on the order of 84% versus 27% in that protocol) and needed a smaller processed blood volume to exchange about 1.2 plasma volumes. Session time was modestly shorter. IgG and IgM reductions were comparable when the target volume was met. The study excluded patients who needed plasma replacement, so it does not settle TTP device choice.

Other head-to-head work has likewise found centrifugal devices often finish faster because they extract plasma more efficiently per milliliter of blood processed. Membrane systems can still deliver a full exchange if run long enough at adequate flow. ICU narrative reviews note that membrane devices are common in critical care because dialysis staff already use filters, while citrate toxicity may be more frequent when higher blood flow and lower plasma-removal efficiency leave more citrate in the patient.

Disease evidence still sits on the indication, not the rotor. NHLBI describes hospital TPE for TTP without requiring a consumer to pick a centrifuge brand. AAN GBS guidance is about plasma exchange as a treatment modality versus IVIG, not about membrane pores. ASFA fact sheets specify TPE as the procedure class. There is no ASFA Category I for “centrifugal longevity” or “membrane detox.”

Access data from the membrane-versus-centrifuge crossover work also matter clinically: almost all participants had central venous access, which is typical when flow must stay high. That is a reminder that “which machine” often collapses into “which catheter.” A longevity brochure that promises a gentle peripheral centrifuge session may still convert to a neck or groin line if veins fail, and that conversion is when infection and clotting risk jump.

Common myths

Myth: Membrane TPE is not real TPE. Fact: ASFA lists membrane filtration as one of two standard ways to separate plasma. Nephrology-run mTPE can be appropriate medical care.

Myth: A faster centrifuge means better anti-aging. Fact: Shorter chair time is an operations finding. It is not a mortality or function outcome in healthy adults. Longevity claims remain animal- and biomarker-level speculation.

Myth: Filters “clean” blood like a water pitcher, so you do not need replacement fluid. Fact: Standard TPE discards plasma. Volume and protein must be replaced or the patient becomes hypovolemic and hypoproteinemic. Double-filtration and other selective methods are different procedures with their own evidence, not a spa upgrade.

Myth: Peripheral IVs make it wellness. Fact: Some cTPE runs on peripheral veins; many mTPE runs need a central catheter. Access route follows flow, not marketing. Central lines raise infection and clotting stakes in either method.

How clinics use it

Hospital apheresis programs often use centrifugal devices (examples in trials include Spectra Optia) staffed by transfusion-medicine teams. ICUs and dialysis units may use membrane TPE when a centrifuge is unavailable or when the patient is already on a dialysis catheter. Replacement fluid still follows the disease: plasma for TTP, albumin for many neurologic and hyperviscosity exchanges.

Longevity clinics that own one machine may offer only that method, on a cash schedule, with limited after-hours coverage. That is a logistics fact, not proof of superiority. If they cannot manage circuit clotting, severe hypocalcemia, or line sepsis, the hardware is irrelevant. ASFA patient sheets describe plasma exchange as a medical procedure with trained staff—not a device demo.

Device choice should never delay indicated TPE. If a patient with suspected TTP is in a hospital that only has membrane capability, starting mTPE with plasma replacement is care. Waiting for a boutique centrifuge is not.

Ask the team how they anticoagulate the circuit. Citrate is common on centrifugal systems; heparin appears more often on some membrane setups. Each path has a different bleeding and hypocalcemia profile. ICU reviews treat that choice as a safety decision for a sick patient, not a wellness preference. If no one can describe calcium replacement or circuit-clot rescue, the method conversation is incomplete.

Practical takeaway

Ask which method will be used and why, but spend more questions on indication, replacement fluid, access, and emergency coverage. Confirm the ordered plasma volume and how they monitor ionized calcium. Ask whether a hematologist, neurologist, or nephrologist owns the order.

Do not pick a clinic because its brochure says centrifugal, hospital-grade, or “the same filter as dialysis.” Those phrases describe plumbing. They do not create an ASFA indication or erase infection, clotting, hypocalcemia, and catheter harm. For TTP, GBS, MG crisis, or hyperviscosity, go where the specialty team can run TPE now.

For aging, method debates are a distraction. Neither cTPE nor mTPE is established preventive care. If you still consider elective exchange, you are accepting a hospital-class procedure’s risks for an unproven goal. That decision should be explicit, costly in time and money, and easy to decline. Write down the plasma volume, fluid, access, and who to call if the line looks infected. If those items are missing, you do not have a method—you have a brochure.